StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38+0.00 (0.00%)

Close on Nov 18, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Inhibikase Therapeutics's price to sales ratio was 229.4× on Oct 31, 2024, against 18.6× a year earlier. Over the last 4 years it ranged from 4.1× to 229.4×, with a median of 21.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Oct 31, 2024229.4×+208.4
2023Dec 29, 202321.0×+16.9
2022Dec 30, 20224.1×−8.3
2021Dec 31, 202112.4×–

More Inhibikase Therapeutics figures

See a number that looks wrong?